Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
Koumarianou A, Karayannopoulou G, Gourgioti G, Batistatou A, Bobos M, Efstratiou I, Miliaras D, Galani E, Pentheroudakis G, Pectasides D, Aravantinos G, Bafaloukos D, Papakostas P, Razis E, Kalofonos HP, Petraki K, Sotiropoulou M, Kalogeras KT, Fountzilas G. Koumarianou A, et al. Among authors: galani e. Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3. Epub 2015 May 7. Cancer Chemother Pharmacol. 2015. PMID: 25947084
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Skarlos DV, Bai M, Goussia A, Samantas E, Galani E, Tsavdaridis D, Karina M, Papakostas P, Konstantara A, Fountzilas G. Skarlos DV, et al. Among authors: galani e. Anticancer Res. 2007 Jul-Aug;27(4C):2973-83. Anticancer Res. 2007. PMID: 17695481 Free article. Clinical Trial.
Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
Skarlos DV, Timotheadou E, Galani E, Samantas E, Grimani I, Lianos E, Aravantinos G, Xanthakis I, Pentheroudakis G, Pectasides D, Fountzilas G. Skarlos DV, et al. Among authors: galani e. Oncology. 2009;77(2):107-12. doi: 10.1159/000229504. Epub 2009 Jul 21. Oncology. 2009. PMID: 19622901
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Koutras AK, et al. Among authors: galani e. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. Pharmacogenomics J. 2012. PMID: 21844885 Clinical Trial.
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, Fountzilas G. Pentheroudakis G, et al. Among authors: galani e. BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49. BMC Cancer. 2013. PMID: 23374602 Free PMC article.
The prognostic role of ephrin A2 and endothelial growth factor receptor pathway mediators in patients with advanced colorectal cancer treated with cetuximab.
Strimpakos A, Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Andreadou A, Sgouros J, Zizi-Sermpetzoglou A, Kominea A, Televantou D, Razis E, Galani E, Pectasides D, Tejpar S, Syrigos K, Fountzilas G. Strimpakos A, et al. Among authors: galani e. Clin Colorectal Cancer. 2013 Dec;12(4):267-274.e2. doi: 10.1016/j.clcc.2013.07.001. Epub 2013 Sep 17. Clin Colorectal Cancer. 2013. PMID: 24050852
Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes.
Mountzios G, Aivazi D, Kostopoulos I, Kourea HP, Kouvatseas G, Timotheadou E, Zebekakis P, Efstratiou I, Gogas H, Vamvouka C, Chrisafi S, Stofas A, Pentheroudakis G, Koutras A, Galani E, Bafaloukos D, Fountzilas G. Mountzios G, et al. Among authors: galani e. PLoS One. 2014 Mar 17;9(3):e91407. doi: 10.1371/journal.pone.0091407. eCollection 2014. PLoS One. 2014. PMID: 24637962 Free PMC article.
Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial.
Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G. Pentheroudakis G, et al. Among authors: galani e. PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612. eCollection 2015. PLoS One. 2015. PMID: 25970543 Free PMC article. Clinical Trial.
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials.
Kotoula V, Chatzopoulos K, Lakis S, Alexopoulou Z, Timotheadou E, Zagouri F, Pentheroudakis G, Gogas H, Galani E, Efstratiou I, Zaramboukas T, Koutras A, Aravantinos G, Samantas E, Psyrri A, Kourea H, Bobos M, Papakostas P, Kosmidis P, Pectasides D, Fountzilas G. Kotoula V, et al. Among authors: galani e. Oncotarget. 2016 Jan 26;7(4):5074-87. doi: 10.18632/oncotarget.6231. Oncotarget. 2016. PMID: 26506242 Free PMC article.
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia.
Mountzios G, Aravantinos G, Alexopoulou Z, Timotheadou E, Matsiakou F, Christodoulou C, Laschos K, Galani E, Koutras A, Bafaloukos D, Linardou H, Pectasides D, Varthalitis I, Papakostas P, Kalofonos HP, Fountzilas G. Mountzios G, et al. Among authors: galani e. Mol Clin Oncol. 2016 Feb;4(2):211-220. doi: 10.3892/mco.2015.693. Epub 2015 Dec 4. Mol Clin Oncol. 2016. PMID: 26893865 Free PMC article.
44 results